Posted 21st October 2024
Posted 3 months ago
By Pfizer
Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Clinical trials, studies & innovative projects
There is a host of clinical trials/studies and innovative projects underway in the network. We will bring you up-to-date information on these as we get the data.
New Therapies
Posted 10th October 2024
Posted 3 months ago
By NHP Office
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Posted 4th October 2024
Posted 3 months ago
By NHS England
NHS England on Oxbryta (Voxelotor) Withdrawal From the UK Market
NHS England sends a letter to centres regarding the 25.09.2024 withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.
Posted 25th September 2024
Posted 4 months ago
By NHP Office
Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
Learning Materials
Posted 14th June 2023
Posted 2 years ago
By NHP Office
NHP TCD In Sickle Cell Disorder Webinar- Learning
NHP TCD in SCD Webinar held on 14 June 2023.
Posted 26th January 2022
Posted 3 years ago
By NHP Office
New Therapies Session- ASCAT 2022
View 3 insightful presentations with Q&A from the New Therapies Session at the virtual ASCAT 2022.
